NEW YORK (GenomeWeb News) - Shares in Stratagene were down approximately 6 percent, or $.43, at $6.41 in mid-afternoon trading today after the company said that litigation-related charges swung second-quarter earnings to a loss.
As GenomeWeb News reported this morning, Stratagene said total revenues were down 6 percent to $23.4 million due to poor sales of its gene-discovery and cloning systems products.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.